These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36336829)

  • 21. Competitive pricing within pharmaceutical classes: evidence on "follow-on" drugs in Germany 1993-2008.
    Mueller MT; Frenzel A
    Eur J Health Econ; 2015 Jan; 16(1):73-82. PubMed ID: 24370790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trends in Prices of Popular Brand-Name Prescription Drugs in the United States.
    Wineinger NE; Zhang Y; Topol EJ
    JAMA Netw Open; 2019 May; 2(5):e194791. PubMed ID: 31150077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How competition lowers the costs of medicines.
    Reekie WD
    Pharmacoeconomics; 1998; 14 Suppl 1():107-13. PubMed ID: 10186472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
    Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
    Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Value-based performance arrangements for chronic conditions: an economic simulation of Medicaid Drug Rebate Program reforms.
    Quinn C; Ciarametaro M; Sils B; Phares S; Trusheim MR
    Expert Rev Pharmacoecon Outcomes Res; 2023 Jun; 23(5):535-546. PubMed ID: 36987666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does reimportation reduce price differences for prescription drugs? Lessons from the European Union.
    Kyle MK; Allsbrook JS; Schulman KA
    Health Serv Res; 2008 Aug; 43(4):1308-24. PubMed ID: 18355258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. International comparison of generic medicine prices.
    Simoens S
    Curr Med Res Opin; 2007 Nov; 23(11):2647-54. PubMed ID: 17877848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trends in Prices of Drugs Used to Treat Metastatic Non-Small Cell Lung Cancer in the US From 2015 to 2020.
    Desai A; Scheckel C; Jensen CJ; Orme J; Williams C; Shah N; Leventakos K; Adjei AA
    JAMA Netw Open; 2022 Jan; 5(1):e2144923. PubMed ID: 35076701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parallel imports of pharmaceuticals in the European Union.
    Darbà J; Rovira J
    Pharmacoeconomics; 1998; 14 Suppl 1():129-36. PubMed ID: 10186474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Medicaid Rebate: Changes in Oncology Drug Prices After the Affordable Care Act.
    Bonakdar Tehrani A; Carroll NV
    Appl Health Econ Health Policy; 2017 Aug; 15(4):513-520. PubMed ID: 28224469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medicaid program; time limitation on price recalculations and recordkeeping requirements under the drug rebate program. Final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2003 Aug; 68(168):51912-7. PubMed ID: 12962118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Commercial importation of prescription drugs in the United States: short-run implications.
    Danzon PM; Johnson SJ; Long G; Furukawa MF
    J Health Polit Policy Law; 2011 Apr; 36(2):295-316. PubMed ID: 21543707
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Drug Rebates and Competition With Out-of-Pocket Coinsurance in Medicare Part D, 2014 to 2018.
    Lakdawalla D; Li M
    JAMA Netw Open; 2021 May; 4(5):e219030. PubMed ID: 33950205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach.
    Augurzky B; Göhlmann S; Gress S; Wasem J
    Health Econ; 2009 Apr; 18(4):421-36. PubMed ID: 18677725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Parallel imports and innovation in an emerging economy: the case of Indian pharmaceuticals.
    Mantovani A; Naghavi A
    Health Econ; 2012 Nov; 21(11):1286-99. PubMed ID: 23027711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Parallel import of drug preparations. A study of price development of parallel import preparations versus original preparations].
    Schou HS
    Ugeskr Laeger; 1993 Jun; 155(26):2024-8. PubMed ID: 8328041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Price regulation of pharmaceuticals in Canada.
    Anis AH; Wen Q
    J Health Econ; 1998 Jan; 17(1):21-38. PubMed ID: 10176313
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does the market share of generic medicines influence the price level?: a European analysis.
    Dylst P; Simoens S
    Pharmacoeconomics; 2011 Oct; 29(10):875-82. PubMed ID: 21797288
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.